41 results about "Dose group" patented technology

The invention discloses a traditional Chinese medicine cancer toxin prescription for treating liver cancer and application thereof in the preparation of medicaments for resisting liver cancer. The cancer toxin prescription is prepared in accordance with the cancer toxin theory proposed by traditional Chinese medicine master Professor Zhou Zhongying, and is prepared from hedyotidis herba, muscardine silkworm, centipede, akebia fruit, pseudostellaria root, dwarf lilyturf root and rhizoma pleionis according to a certain weight ratio. The prescription has the main functions of eliminating pathogens, eliminating cancer and detoxicating and the auxiliary function of strengthening healthy qi. By using mice with liver cancer H22 transplantation tumor as materials, the pharmacological experiment result shows the cancer resistance effect of the cancer toxin prescription: the tumor inhibition rates of a low-dose group, an intermediate-dose group and a high-dose group are respectively 24.5%, 42.8% and 21.1%, thereby showing the effect of inhibiting the growth of H22 tumor mass; the tumor mass cell apoptosis rates of the low-dose group, the intermediate-dose group and the high-dose group are respectively 47.16%, 60.52% and 57.59%, thereby showing the effect of inducing tumor cells to die; and the cancer toxin prescription can block the high expression of TLR4, block the MyD88 dependent pathway of TLR4 intracellular signal transduction and inhibit the expression of downstream NF-kB proteins. Experiment shows that the cancer toxin prescription can be used for preparing medicaments for resisting liver cancer.

The invention relates to the technical field of application of allicin, and relates to the application of an allicin multi-layer enteric-coated tablet as a drug for the treatment of myocardial infarction. The results of the histopathological examination of the rat myocardial infarction animal model and the biochemical index examination of blood and heart tissue homogenate showed that allicin multi-layer enteric-coated tablets have anti-myocardial infarction effect, and the difference between each dose group A significant dose-dependent relationship is presented, indicating that the allicin multilayer enteric-coated tablet can effectively prevent and treat myocardial infarction, and further indicates that the allicin preparation can become a new drug preparation for efficiently treating myocardial infarction.

The invention discloses a cup set with a single quantitative addition function, made of a transparent material and comprising a connection plate (1); one side of the connection plate is connected withmultiple test cup units (2), the surface of the other side of the connection plate is provided with multiple passage units, each passage unit is formed by mutually communicating a main passage (3), abranch passage (4) and a downflow branch passage (8), one end of every passage unit is connected with a liquid inlet (5) arranged in the connection plate, the other end of every passage unit is communicated with an inner cavity of the corresponding test cup (2) through its quantitative hole (9), suitable dry test agent is attached to the bottom of each test cup (2), the passage units form a fluidflowing pipeline after the passage unit surface of the connection plate is sealed with a cover plate (7), such pipeline serves as a unique channel open to the outside from the test cups (2), and accordingly, quantitative liquid can be added into multiple test cups at a time.